Treatment of overactive bladder with modified intravesical oxybutynin chloride

Saito, Motoaki; Tabuchi, Fumie; Otsubo, Kenji; Miyagawa, Ikuo

doi:10.1002/1520-6777(2000)19:6<683::aid-nau6>3.0.co;2-r

Cited by 28 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hughes et al (32) reported that high levels of orally administered oxybutynin were matched by high DEOB metabolite levels in young, elderly and frail elderly volunteers. Moreover, Saitoh et al (33) also reported that plasma levels of oxybutynin were almost equal to those of DEOB even in the instillation of intravesical oxybutynin in overactive bladder patients. In the present in vivo experiment, we used 0.3 mg / kg as the dose of DEOB administered intravenously.…”

Section: Discussionmentioning

confidence: 95%

Effects of 4-Ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate Hydrochloride, a Metabolite of Oxybutynin, on Bladder Specimens and Rhythmic Bladder Contraction in Rats in Comparison With Oxybutynin

et al. 2004

View full text Add to dashboard Cite

Abstract. Oxybutynin has been used for neurogenic bladder disorders and is known to have anti-cholinergic and antispasmodic properties. However, the anti-cholinergic and antispasmodic properties of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride (N-desethyloxybutynin: DEOB), a metabolite of oxybutynin, have not been clarified. Therefore, in the present study, we studied these properties by using rat urinary bladder specimens in comparison with oxybutynin. Moreover, the effect of DEOB on rhythmic urinary bladder contraction was also evaluated using anesthetized rats. DEOB and oxybutynin concentration-dependently inhibited the carbachol-induced contraction, the pA 2 values being 7.19 and 7.11, respectively. DEOB and oxybutynin also concentration-dependently inhibited the 100 mM KCl-induced contraction, the ED 50 values being 12.1 and 10.4 mM, respectively. Intravenously administered DEOB and oxybutynin dose-dependently (0.03 -0.3 mg / kg) inhibited the amplitude of the rhythmic bladder contraction to similar degrees, but had no affect on the frequency. From the above results, it was determined that DEOB has anti-cholinergic and antispasmodic properties and that these activities were almost equal to those of oxybutynin. Therefore, DEOB may play an important role during oxybutynin therapy for neurogenic bladder disorder.

show abstract

Section: Discussionmentioning

confidence: 95%

Effects of 4-Ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate Hydrochloride, a Metabolite of Oxybutynin, on Bladder Specimens and Rhythmic Bladder Contraction in Rats in Comparison With Oxybutynin

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Intravesical oxybutynin modified with a mucosal adherence substance, hydroxypropyl cellulose, may cause fewer adverse events due to reduced absorption of oxybutynin from bladder mucosa [28,29]. Improvement in cystometric bladder capacity and compliance occurred in all after 1 week and improved further at 1 year in three patients.…”

Section: Clinical Studiesmentioning

confidence: 95%

Neurogenic Bladder: Current Pharmacologic Trends

Cameron

Latini

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Several studies have investigated the many pharmacologic therapies to treat neurogenic bladder. Our aim with this review is to provide an update on the current clinical and basic science literature pertaining to pharmacotherapy for this condition. Advances have been made in pediatric and adult pharmacotherapy. The most notable include the safety and effective use of tolterodine and transdermal oxybutynin in the treatment of pediatric neurogenic bladder. Also, recently, the safe and effective triple drug therapy consisting of an antimuscarinic, an α-blocker, and imipramine in combination has been shown to significantly improve bladder compliance and detrusor pressures.

show abstract

“…Sa combinaison à des agents favorisant l'adhésion à la muqueuse vésicale, tels l'hydroxypropylcellulose [8,20] ou son administration motivée par électrophorèse [20], se sont révélés intéressants à court terme mais la pertinence théra-peutique au long cours et la faisabilité de ces procédés, sont méconnues. L'intérêt de la combinaison d'anticholinergiques oraux et endovésicaux a été souligné par un travail ouvert mené chez 25 blessés médullaires dont l'hyperactivité du détrusor et les hautes pressions du détrusor étaient mal contrôlées par les anticholinergiques oraux [21].…”

Section: Les Anticholinergiquesunclassified

Intérêt des thérapies intravésicales en neuro-urologie

Sèze

Delleci

Ruffion³

2009

Acta Endosc

View full text Add to dashboard Cite

Intravesical instillation therapy is an easy way to provide high concentrations of pharmacological agents to bladder tissue without causing significant systemic side effects. Urethral catheterization is frequently used for bladder management and follow-up in neurological patients, making such treatment easy to administer in this population. Several agents have been suggested, acting on either the afferent or efferent arm of the micturition reflex, for the treatment of hyperactive or underactive detrusor in patients who do not respond to first-line oral therapies. Despite the established interest of some agents, their use is limited by the lack of commercially available solutions and/or the short duration of the therapeutic effect, resulting in under-use of this promising approach.

show abstract

Treatment of overactive bladder with modified intravesical oxybutynin chloride

Cited by 28 publications

References 13 publications

Effects of 4-Ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate Hydrochloride, a Metabolite of Oxybutynin, on Bladder Specimens and Rhythmic Bladder Contraction in Rats in Comparison With Oxybutynin

Effects of 4-Ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate Hydrochloride, a Metabolite of Oxybutynin, on Bladder Specimens and Rhythmic Bladder Contraction in Rats in Comparison With Oxybutynin

Neurogenic Bladder: Current Pharmacologic Trends

Intérêt des thérapies intravésicales en neuro-urologie

Contact Info

Product

Resources

About